TrialRheumatology (Oxford, England)2022

Certolizumab pegol treatment in axial spondyloarthritis mitigates fat lesion development: 4-year post-hoc MRI results from a phase 3 study.

Xenofon Baraliakos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.